Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Update on the role of lenalidomide in patients with multiple myeloma.

Holstein SA, Suman VJ, McCarthy PL.

Ther Adv Hematol. 2018 Jul;9(7):175-190. doi: 10.1177/2040620718775629. Epub 2018 May 26. Review.

2.

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.

Raza S, Safyan RA, Lentzsch S.

Curr Cancer Drug Targets. 2017;17(9):846-857. doi: 10.2174/1568009617666170214104426. Review.

PMID:
28201976
3.

Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Holstein SA, McCarthy PL.

Drugs. 2017 Apr;77(5):505-520. doi: 10.1007/s40265-017-0689-1. Review.

4.

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Richardson PG, Holstein SA, Schlossman RL, Anderson KC, Attal M, McCarthy PL.

Expert Opin Pharmacother. 2017 Dec;18(18):1975-1985. doi: 10.1080/14656566.2017.1409207. Epub 2017 Dec 1. Review.

PMID:
29172855
5.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
6.

Thalidomide and lenalidomide in the treatment of multiple myeloma.

Kumar S, Rajkumar SV.

Eur J Cancer. 2006 Jul;42(11):1612-22. Epub 2006 Jun 5. Review.

PMID:
16750621
7.

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.

van de Donk NW, Lokhorst HM.

Expert Opin Pharmacother. 2013 Aug;14(12):1569-73. doi: 10.1517/14656566.2013.805746. Epub 2013 May 31.

PMID:
23721099
8.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
9.

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.

Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA.

Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498. Print 2013.

10.

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.

Moreau P.

Semin Hematol. 2012 Jul;49 Suppl 1:S33-46. doi: 10.1053/j.seminhematol.2012.05.004.

PMID:
22727391
11.

Immunomodulatory drugs in multiple myeloma.

Andhavarapu S, Roy V.

Expert Rev Hematol. 2013 Feb;6(1):69-82. doi: 10.1586/ehm.12.62. Review.

PMID:
23373782
12.

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

Morgan G.

Blood Rev. 2010 Nov;24 Suppl 1:S27-32. doi: 10.1016/S0268-960X(10)70006-0.

PMID:
21126634
13.

An update on the use of lenalidomide for the treatment of multiple myeloma.

Zagouri F, Terpos E, Kastritis E, Dimopoulos MA.

Expert Opin Pharmacother. 2015;16(12):1865-77. doi: 10.1517/14656566.2015.1067681. Epub 2015 Jul 13. Review.

PMID:
26165832
14.

Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.

Syed YY.

Drugs. 2017 Sep;77(13):1473-1480. doi: 10.1007/s40265-017-0795-0. Review.

PMID:
28791622
15.

Evaluation of immunomodulatory drugs in multiple myeloma: single center experience.

Ozkan MC, Tombuloglu M, Sahin F, Saydam G.

Am J Blood Res. 2015 Dec 25;5(2):95-100. eCollection 2015.

16.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A.

Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.

17.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83. Review.

PMID:
21322778
18.

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K.

Core Evid. 2010 Jun 15;4:215-45.

19.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

20.

Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.

Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA.

Cancer J. 2019 Jan/Feb;25(1):2-10. doi: 10.1097/PPO.0000000000000348.

PMID:
30694854

Supplemental Content

Support Center